Keywords: estimated, 740m, pipeline, genmab, denmark-based, biotechnology, company

An estimated $740M pipeline for Genmab

Article | 18 March 2002

Denmark-based Genmab, the biotechnology company specializing in thedevelopment of human monoclonal antibodies in the areas of chronic inflammatory disease (rheumatoid ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Roche

Go to company listing